HK Stock Market Move | Biocytogen Pharmaceuticals-B (02315) continues to rise by over 6%, reaching a strategic cooperation with SIHUAN PHARM to accelerate the research and development of innovative drugs in weight loss and other fields.

Biocytogen Pharmaceuticals-B (02315) rose by over 6%, at the time of writing, it was up by 6.89%, at HK$67.45, with a trading volume of HK$25.836 million. On the news front, SIHUAN PHARM and Biocytogen Pharmaceuticals have officially signed a strategic cooperation agreement. The two parties will leverage Biocytogen Pharmaceuticals' leading humanized antibody development platform, combined with SIHUAN PHARM's extensive experience in drug development, production, and commercialization, to collaborate and exchange in the research and development of innovative drugs in various disease areas, such as weight loss, to promote complementary advantages and resource synergy, and establish a long-term, stable cooperative relationship. The first collaboration project of this strategic cooperation focuses on the company's new generation weight loss innovative drugs under research. Galaxy Securities previously pointed out that Biocytogen Pharmaceuticals, with gene editing technology as its cornerstone, benefits greatly from the industry's upswing cycle dividends in its preclinical products and services business. As the company's major investment in the Thousand Mouse and Ten Thousand Antigen program enters the realization phase, the company's performance is expected to bring substantial growth.